Abstract: In a process for the continuous recovery of free tartaric acid from raw materials containing potassium hydrogentartrate, the same are mixed with water and the potassium hydrogentartrate is dissolved. The process is improved in that the suspension is decanted, the clarified liquid is refiltered, the filtrate is cooled to crystallization temperature under a vacuum, the potassium hydrogentartrate crystals formed are dissolved, the solution is subjected to a cation exchange, and the tartaric acid solution obtained is evaporated.

Abstract: Disclosed are compounds of general formula (I), wherein the groups R1, R2, Ra and Rb have the meanings given in the claims and specification, the tautomers, racemates, enantiomers, diastereomers and the mixtures thereof, and optionally the pharmacologically acceptable acid addition salts, solvates and hydrates thereof, and processes for preparing these thiazolyl-dihydro-indazoles and the use thereof as pharmaceutical compositions.

Abstract: Disclosed are thiazolyl-dihydro-quinazolines of general formula (I) wherein the groups R1 to R4 have the meanings given in the claims and specification, the isomers thereof, and processes for preparing these compounds and their use as pharmaceutical compositions.

Abstract: Disclosed are compounds of general formula (I), wherein the groups A, R1, R2, Ra and Rb have the meanings given in the claims and specification, the tautomers, racemates, enantiomers, diastereomers and the mixtures thereof, and optionally the pharmacologically acceptable acid addition salts, solvates and hydrates thereof, and processes for preparing these thiazolyl-dihydro-quinazolines and the use thereof as pharmaceutical compositions.

Abstract: The present invention relates to new thiazolyl-dihydro-indazoles of general formula (I) wherein the groups R1, R2 and R3 have the meanings given in the claims and specification, the tautomers, racemates, enantiomers, diastereomers and the mixtures thereof, and optionally the pharmacologically acceptable acid addition salts, solvates and hydrates thereof, and processes for preparing these thiazolyl-dihydro-indazoles and the use thereof as pharmaceutical compositions.

Abstract: Disclosed are compounds of general formula (I), wherein the groups R1, R2, Ra and Rb have the meanings given in the claims and specification, the tautomers, racemates, enantiomers, diastereomers and the mixtures thereof, and optionally the pharmacologically acceptable acid addition salts, solvates and hydrates thereof, and processes for preparing these thiazolyl-dihydro-cyclopentapyrazoles and the use thereof as pharmaceutical compositions.

Abstract: In the process for the continuous recovery of free tartaric acid from raw materials containing potassium hydrogentartrate, the same are mixed with water and the potassium hydrogentartrate is dissolved. The process is improved in that the suspension is decanted, the clarified liquid is refiltered, the filtrate is cooled to crystallization temperature under a vacuum, the potassium hydrogentartrate crystals formed are dissolved, the solution is subject to a cation exchange, and the tartaric acid solution obtained is evaporated.

Abstract: This invention is directed to methods of preventing or reducing the severity of asthma or the risk of development of same in an individual. The method relies on administration to the airways of the individual of an immunologically effective dose of a mycobacterium based vaccine. The mycobacteria are effective in inducing a Th1 type immune response in the individual.

Abstract: This invention is directed to methods of preventing or reducing the severity of asthma or the risk of development of same in an individual. The method relies on administration to the airways of the individual of an immunologically effective dose of a mycobacterium based vaccine. The mycobacteria are effective in inducing a Thl type immune response in the individual.

Abstract: Process for producing tartaric acid from a raw material whose dry matter comprises at least 5 wt% potassium hydrogentartrate wherein the raw material containing potassium hydrogen tartrate (KHT) is mixed with aqueous potassium hydroxide solution in a first reaction stage, where KHT is virtually completely reacted to form dipotassium tartrate (DKT), the aqueous solution containing DKT is then mixed with added acid in a precipitation stage at a pH value of 2.0 to 5.0, to produce a suspension containing crystallized KHT; crystallized KHT is then separated from the suspension, washed with water, and there is produced a solution at least 80 wt-% saturated with KHT and then the potassium is removed, to obtain an aqueous tartaric acid product solution, from which water is then at least partly removed.